TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05833919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes.~The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes.~The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
Study: NCT01898052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single anaesthetic drug
Description: inject periarticular tissue of the knee after implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multimodal drug injection
Description: inject periarticular tissue of the knee
Study: NCT03455712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestational Weight Gain Card
Description: The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
Study: NCT04472897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2556286
Description: GSK2556286 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2556286
Description: GSK2556286 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study: NCT01570140

Intervention type: BEHAVIORAL
Intervention: Web portal
Description: This study investigates the effects of the voluntarily use of a webportal and its educational content.
Study: NCT02677415

Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous anesthetics

Intervention type: OTHER
Group type: OTHER
Intervention: local anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Spontaneous breathing
Study: NCT03752476

Intervention type: PROCEDURE
Intervention: number of Beta lactam class prescription for the same infection
Description: Each number of Beta lactam prescription without interruption are compared

Intervention type: PROCEDURE
Intervention: number of Beta lactam class prescription for the same infection
Description: Each number of Beta lactam prescription without interruption are compared
Study: NCT01973686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study: NCT02050139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-cysteine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03613714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: At-home Blood Pressure Monitoring
Description: Participants will use over-the-counter digital monitor to measure blood pressure and pulse rate at home. Automatically averages the last 3 readings taken over 10 minutes.
Study: NCT02089802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT00416819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT02508376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AP10-602
Description: AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AP10-602
Description: AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93
Description: ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93
Description: ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93
Description: ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93
Description: ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
Study: NCT03258645

Intervention type: DRUG
Intervention: Dabigatran
Description: Oral anticoagulant (NOAC) thrombin inhibitor
Study: NCT01772927

Intervention type: DIETARY_SUPPLEMENT
Intervention: Parenteral Nutrition
Description: Protein and energy intakes
Study: NCT04195724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mNGS for pathogen detection
Description: mNGS for pathogen detection and metabonomics (ascites, fecal,venous blood from superior mesenteric vein, hepatic vein and peripheral vein, respectively)
Study: NCT00078403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 mcg PEG-IFN subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 mcg PEG-IFN subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 mcg PEG-IFN subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: One tablet or capsule containing ribavirin 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: One tablet or capsule containing ribavirin 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: One tablet or capsule containing ribavirin 200 mg
Study: NCT02702843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with Xenon light
Description: Standard laparoscopic cholecystectomy with white light

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy with Xenon light
Description: Standard laparoscopic cholecystectomy with white light

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (fluorescent cholangiography)
Description: Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
Study: NCT03002545

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium citrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02171429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Etrolizumab Placebo
Description: Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Etrolizumab Placebo
Description: Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study: NCT02458560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards CENTERA Self-Expanding Transcatheter Heart Valve
Description: The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
Study: NCT02100280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep block
Description: sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
Study: NCT00977912

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Description: one capsule containing probiotics per day added to milk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk containing placebo
Description: one capsule containing placebo per day added to milk
Study: NCT01668056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation induction with choriogonadotropin alfa
Description: Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration of the dominant follicle
Description: Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
Study: NCT03141190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction - modified
Description: already described

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active listening and reading
Description: group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
Study: NCT01675492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
Study: NCT03055247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myelostim
Description: Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are \< 10 /μL) to the day of the last LP.
Study: NCT02801825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
Description: Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided out-of-plane femoral artery cannulation.
Description: Real-time ultrasound-guided out-of-plane femoral artery cannulation.
Study: NCT03145753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV/HCV Education plus Testing
Description: Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIV/HCV Education
Description: Only education and support will be provided in this arm
Study: NCT02999334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Antenatal Care
Description: To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
Study: NCT01005862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: 10 mg/kg, single dose administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00856791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Study: NCT01751750

Intervention type: OTHER
Group type: OTHER
Intervention: Grape
Description: 16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
Study: NCT03113669

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT-GSH
Study: NCT00455000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: Monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03894839

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glutaraldehyde disinfection and microwave application
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate disinfection and microwave application
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite disinfection and microwave application
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glutaraldehyde disinfection and ozone therapy
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate disinfection and ozone therapy
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite disinfection and ozone therapy
Description: Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
Study: NCT02459197

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heat Pain Stimuli A
Study: NCT03804177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement with melatonin hyaluronic acid vit C
Description: immediate implant placement with melatonin and hyaluronic acid and systemic administration vitamin C

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement without melatonin hyaluronic acid vit C
Description: immediate implant placement without melatonin and hyaluronic acid and systemic administration vitamin C
Study: NCT03693976

Intervention type: DRUG
Intervention: Xylometazoline Nasal Spray
Description: Application of Xylometazoline Nasal Spray in accordance with the instructions for use

Intervention type: DRUG
Intervention: Xylometazoline Nasal Spray
Description: Application of Xylometazoline Nasal Spray in accordance with the instructions for use

Intervention type: DEVICE
Intervention: Ectoin Rhinosinusitis Nasal Spray
Description: Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use

Intervention type: DEVICE
Intervention: Ectoin Rhinosinusitis Nasal Spray
Description: Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use
Study: NCT01357122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCI Insertion
Description: DSAEK surgery will be performed using the NCI to insert the donor tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Forceps Insertion
Description: DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
Study: NCT02102438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Paclitaxel
Description: Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
Study: NCT04221464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological collection
Description: Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissues collections
Description: Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
Study: NCT02459197

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Heat Pain Stimuli B

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Video

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Video

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of T4P1001 capsules
Description: This treatment is given as add-on therapy to patient's regular analgesic treatment

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Administration of Placebo capsules
Description: This treatment is given as add-on therapy to patient's regular analgesic treatment